Blueprint and Elicio among biotechs to advance cause at ASCO

05-06-2023Comments (0)Print

06-06-2023

30-03-2023

18-01-2023

17-05-2022

06-06-2023

06-06-2023

06-06-2023

Along with the big pharma players showing off the potential of their cancer drugs at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), biotech companies have been making their presence felt, too.

Examples are the precision therapy company Blueprint Medicines (Nasdaq: BPMC) and Elicio Therapeutics (Nasdaq: ELTX), a biotech developing a pipeline of immunotherapies for the treatment of cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

• All the news that moves the needle in pharma and biotech.• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. • Receive The Pharma Letter daily news bulletin, free forever.

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.• Daily roundup of key events in pharma and biotech.• Monthly in-depth briefings on Boardroom appointments and M&A news.• Choose from a cost-effective annual package or a flexible monthly subscription.

ASCOBiotechnologyBLU-222BLU-451BLU-945Blueprint MedicinesConferencesDrug TrialELI-002Elicio TherapeuticsFocus OnImmuno-oncologyOncologyOne to Watch CompaniesResearchUSA